| Publications | PubMed=978138; DOI=10.1084/jem.144.4.873; PMCID=PMC2190439
Hiroshi Shiku, Toshitada Takahashi, Herbert Friedrich Oettgen, Lloyd John Old;
Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens.
J. Exp. Med. 144:873-881(1976) PubMed=1067619; DOI=10.1073/pnas.73.9.3278; PMCID=PMC431008
Thomas E. Carey, Toshitada Takahashi, Lois A. Resnick-Silverman, Herbert Friedrich Oettgen, Lloyd John Old;
Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells.
Proc. Natl. Acad. Sci. U.S.A. 73:3278-3282(1976) PubMed=327080; DOI=10.1093/jnci/59.1.221
Jorgen Fogh, Jens M. Fogh, Thomas Orfeo;
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977) PubMed=833871; DOI=10.1093/jnci/58.2.209
Jorgen Fogh, William C. Wright, James D. Loveless;
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977) PubMed=313568; DOI=10.1073/pnas.76.6.2898; PMCID=PMC383717
Thomas E. Carey, Kenneth Oliver Lloyd, Toshitada Takahashi, Luiz Rodolpho Travassos, Lloyd John Old;
AU cell-surface antigen of human malignant melanoma: solubilization and partial characterization.
Proc. Natl. Acad. Sci. U.S.A. 76:2898-2902(1979) PubMed=6933476; DOI=10.1073/pnas.77.7.4260; PMCID=PMC349812
Alan N. Houghton, Michael C. Taormina, Hisami Ikeda, Tadashi Watanabe, Herbert Friedrich Oettgen, Lloyd John Old;
Serological survey of normal humans for natural antibody to cell surface antigens of melanoma.
Proc. Natl. Acad. Sci. U.S.A. 77:4260-4264(1980) DOI=10.1007/978-1-4615-7228-2_39
Alan N. Houghton, Herbert Friedrich Oettgen, Lloyd John Old;
Malignant melanoma. Current status of the search for melanoma-specific antigens.
(In book chapter) Immunodermatology. Comprehensive Immunology, Vol 7; Safai, Bijan & Good, Robert Alan (eds.); pp.557-576; Springer; Boston; USA (1981) PubMed=7017212; DOI=10.1093/jnci/66.6.1003
Marilyn S. Pollack, Socorro D. Heagney, Philip O. Livingston, Jorgen Fogh;
HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.
J. Natl. Cancer Inst. 66:1003-1012(1981) PubMed=7175440; DOI=10.1084/jem.156.6.1755; PMCID=PMC2186870
Alan N. Houghton, Magdalena Eisinger, Anthony P. Albino, J. Gregory Cairncross, Lloyd John Old;
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets.
J. Exp. Med. 156:1755-1766(1982) PubMed=6220172
Nicholas C. Dracopoli, Jorgen Fogh;
Polymorphic enzyme analysis of cultured human tumor cell lines.
J. Natl. Cancer Inst. 70:469-476(1983) PubMed=6864164; DOI=10.1084/jem.158.1.53; PMCID=PMC2187084
Alan N. Houghton, Hannah Brooks, Richard J. Cote, Michael C. Taormina, Herbert Friedrich Oettgen, Lloyd John Old;
Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma.
J. Exp. Med. 158:53-65(1983) PubMed=6582512; DOI=10.1073/pnas.81.2.568; PMCID=PMC344720
Michael Jules Mattes, Carlos Cordon-Cardo, John L. Lewis Jr., Lloyd John Old, Kenneth Oliver Lloyd;
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984) PubMed=2983346; DOI=10.1073/pnas.82.5.1470; PMCID=PMC397284
Nicholas C. Dracopoli, Alan N. Houghton, Lloyd John Old;
Loss of polymorphic restriction fragments in malignant melanoma: implications for tumor heterogeneity.
Proc. Natl. Acad. Sci. U.S.A. 82:1470-1474(1985) PubMed=3972469; DOI=10.1002/ijc.2910350215
Francoise M.Y.R. Vessiere-Louveaux, Martine Darville, Alexander Knuth, Thierry Boon;
Use of irradiated mouse fibroblasts to improve the cloning and adaptation to culture of human melanoma cells.
Int. J. Cancer 35:231-235(1985) PubMed=3518877; DOI=10.3109/07357908609038260
Jorgen Fogh;
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986) PubMed=3756862
Kevin Maynard, Peter G. Parsons;
Cross-sensitivity of methylating agents, hydroxyurea, and methotrexate in human tumor cells of the Mer- phenotype.
Cancer Res. 46:5009-5013(1986) PubMed=2784858; DOI=10.1073/pnas.86.8.2804; PMCID=PMC287007
Alexander Knuth, Thomas Wolfel, Eva Klehmann-Hieb, Thierry Boon, Karl-Hermann Meyer zum Buschenfelde;
Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection.
Proc. Natl. Acad. Sci. U.S.A. 86:2804-2808(1989) PubMed=1697409
Georgia Chenevix-Trench, Nicholas Gordon Martin, Kay Adrian Oswald Ellem;
Gene expression in melanoma cell lines and cultured melanocytes: correlation between levels of c-src-1, c-myc and p53.
Oncogene 5:1187-1193(1990) PubMed=1716514
Anthony P. Albino, Brigid M. Davis, David Michael Nanus;
Induction of growth factor RNA expression in human malignant melanoma: markers of transformation.
Cancer Res. 51:4815-4820(1991) PubMed=9354451
Marina Castellano, Pamela M. Pollock, Marilyn K. Walters, Louise E. Sparrow, Louise M. Down, Brian G. Gabrielli, Peter G. Parsons, Nicholas K. Hayward;
CDKN2A/p16 is inactivated in most melanoma cell lines.
Cancer Res. 57:4868-4875(1997) PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N
Graeme J. Walker, Jose F. Flores, J. Michael Glendening, Amy Hsiu-Ti Lin, Isabel D.C. Markl, Jane W. Fountain;
Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
Genes Chromosomes Cancer 22:157-163(1998) PubMed=15048078; DOI=10.1038/sj.onc.1207563
Sandra Pavey, Peter Johansson, Leisl Packer, Jennifer Taylor, Mitchell S. Stark, Pamela M. Pollock, Graeme J. Walker, Glen M. Boyle, Ursula Harper, Sarah-Jane Cozzi, Katherine Hansen ...Show all 20 authors... , Laura Yudt, Chris Schmidt, Peter Hersey, Kay Adrian Oswald Ellem, Michael G.E. O'Rourke, Peter G. Parsons, Paul S. Meltzer, Markus Ringner, Nicholas K. Hayward; Show fewer authors
Microarray expression profiling in melanoma reveals a BRAF mutation signature.
Oncogene 23:4060-4067(2004) PubMed=17516929; DOI=10.1111/j.1600-0749.2007.00375.x
Peter Johansson, Sandra Pavey, Nicholas K. Hayward;
Confirmation of a BRAF mutation-associated gene expression signature in melanoma.
Pigment Cell Res. 20:216-221(2007) PubMed=21725359; DOI=10.1038/onc.2011.250; PMCID=PMC3267014
Feng Xing, Yogindra Persaud, Christine A. Pratilas, Barry Stephen Taylor, Manickam Janakiraman, Qing-Bai She, Humilidad F. Gallardo, C. Liu, Taha Merghoub, Blake E. Hefter, Igor Dolgalev ...Show all 19 authors... , Agnes J. Viale, Adriana Heguy, Elisa de Stanchina, David Cobrinik, Gideon Bollag, Jedd D. Wolchok, Alan N. Houghton, David B. Solit; Show fewer authors
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF.
Oncogene 31:446-457(2012) PubMed=23039341; DOI=10.1186/1476-4598-11-75; PMCID=PMC3554420
Sara A. Byron, David C. Loch, Candice L. Wellens, Andreas Wortmann, Jia-Yi Wu, John Wang, Kenichi Nomoto, Pamela M. Pollock;
Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.
Mol. Cancer 11:75.1-75.15(2012) PubMed=24576830; DOI=10.1158/0008-5472.CAN-13-2625; PMCID=PMC4005042
Moriah Heller Nissan, Christine A. Pratilas, Alexis M. Jones, Ricardo Ramirez, Helen Won, Cai-Lian Liu, Shakuntala Tiwari, Li Kong, Aphrothiti J. Hanrahan, Zhan Yao, Taha Merghoub ...Show all 19 authors... , Antoni Ribas, Paul B. Chapman, Rona D. Yaeger, Barry Stephen Taylor, Nikolaus Schultz, Michael F. Berger, Neal Rosen, David B. Solit; Show fewer authors
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
Cancer Res. 74:2340-2350(2014) |
|---|
